ArticleBlood cancer journal2025

Superior preclinical efficacy of co-treatment with BRG1/BRM and FLT3 inhibitor against AML cells with FLT3 mutations.

Warren Fiskus et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.